The clocks are ticking for Express Scripts, writes Stephen E. Littlejohn. Having achieved formidable “size and scale,” how will the nation’s largest pharmacy benefit manager synchronize with value-based health care?
As the U.S. Open Payments system improves operations and resolves discrepancies, the emergence of widely diverse and contradictory transparency programs in Europe and other nations raises new challenges for pharma, writes Jill Wechsler.
The latest organization to join the cost-effectiveness stampede is the NCCN, which recently announced that it would add a new “tool” to its widely used guidelines that advise oncologists on cancer treatment strategies.
A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.
FDA needs to expand and empower its Office of Health & Constituent Affairs and its Patient Liaison Program to better coordinate interactions with individuals and physicians seeking expedited access to experimental therapies, writes Jill Wechsler.
The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.